Onset: 1–3 hours after oral dose; effects build cumulatively over 2–6 weeks for the central anxiolytic / cognitive arm. Topical applications: hours-to-days for skin texture; weeks for visible scar improvement.

Peak: Hard to identify on single doses — the molecule doesn't produce a discrete "feel" the way phenibut or modafinil does. Most users report a vague calming or "settled" sensation 1–2 hours post-dose at 500 mg, but the signal-to-noise is low compared with ashwagandha or kava.

Duration: 6–10 hours of mild anxiolytic effect with single dose; cumulative steady-state effect with twice-daily dosing.

Characteristic effects (centellosides at 500–1000 mg/day):

• Mild reduction in trait anxiety (more noticeable in high-anxiety users)
• Subjective "clearer thinking" — non-stimulant, not focus-acute; more like reduced mental noise
• Modest mood lift over 2–4 weeks of use
• No euphoria, no stimulation, no sedation in most users
• ~10–15% of users report mild drowsiness, especially at higher doses (>1000 mg)
• Some users report better skin texture / faster bruise resolution at 4–8 weeks
• Negligible effect on sleep architecture
• Negligible effect on cardiovascular signs

Honest variability: Gotu kola is one of the milder herbal interventions on the menu. ~30% of users report "nothing felt" — consistent with the 2017 meta-analysis null finding on cognition. ~20% report clear anxiolytic benefit similar to a mild dose of L-theanine. The remaining ~50% sit somewhere in between, reporting vague benefits that are easy to confuse with placebo or expectancy.

• Pharmacological tolerance: Not well-characterized. Most clinical trials run 4–8 weeks without dose escalation; no published evidence of tolerance development at therapeutic doses.
• Hepatotoxicity-driven cycling discipline: The dominant reason to cycle is not pharmacodynamic tolerance but cumulative hepatic exposure. The case literature pattern of 4–8 week onset for liver injury argues for ≤6 weeks on / ≥2 weeks off as a defensive protocol.
• Recommended cycle for this athlete: 4-week trial → 2-week off → reassess. If beneficial, alternate with another rotation item (ashwagandha or rhodiola) in 4-on/4-off blocks rather than continuous use.
• Reset: None required after a 4-week trial. After a longer continuous run (rare, not recommended), allow 4 weeks fully off before resuming.

Synergistic with

• Bacopa monnieri — classical Ayurvedic "brahmi" pairing. Bacopa for memory consolidation (replicated meta-analysis evidence), gotu kola for anxiolysis + microcirculation. Community-aggregate co-use n=149 (highest co-mention in dopamine.club data). Mechanism: bacopa hits BDNF/serotonin/cholinergic; gotu kola hits GABA + Nrf2 + collagen — minimal overlap, plausible additive cognitive support.
• Ashwagandha (KSM-66 / Sensoril) — both adaptogenic, both modestly anxiolytic. Ashwagandha is the stronger anxiolytic; gotu kola adds microcirculation + skin support. n=98 co-mention.
• L-theanine — fast-onset acute anxiolysis + cognitive support; gotu kola adds chronic GABAergic baseline. n=96.
• Diosmin / hesperidin (venous-tone agents) — additive phlebotonic effect for chronic venous insufficiency; complementary mechanisms (flavonoid venous tone + centelloside microcirculatory repair).
• Vitamin C + zinc — collagen-synthesis cofactors; pair with topical or oral centellosides for wound/scar protocols.
• Pycnogenol — venous-tone + antioxidant synergy.

Avoid stacking with

• Hepatotoxic drugs (isotretinoin, methotrexate, valproate, high-dose acetaminophen, amiodarone) — additive liver-injury risk.
• Alcohol (chronic / heavy) — same.
• Sedatives (benzodiazepines, gabapentin, phenibut) — theoretical additive GABAergic sedation; mild in practice but real.
• Strong anticoagulants (warfarin, full-dose DOACs) — theoretical mild antiplatelet contribution from triterpenoid saponins; clinically minor but flag.
• Cholesterol-lowering statins — both metabolized through CYP3A4; theoretical interaction, clinically minor at typical doses.

Neutral / safe co-administration

• All standard nootropic stack components (citicoline, alpha-GPC, omega-3, vitamin D3/K2, magnesium, NAC, creatine, beta-alanine, PS, curcumin, rhodiola)
• Caffeine — no interaction
• Modafinil — no interaction (theoretical GABAergic offset of glutamatergic effect is mild and not clinically significant)
• Selank — no interaction; both anxiolytic via different mechanisms, additive at most
• BPC-157, TB-500, other regenerative peptides — synergistic for wound/recovery applications

Gotu kola's metabolic profile:

• Hepatic glucuronidation + CYP3A4 oxidation are primary clearance routes for asiatic and madecassic acid
• Mild theoretical CYP3A4 inhibition at high doses (in vitro signal); clinical relevance minor at standard doses
• Biliary excretion of glucuronide metabolites

Clinically significant interactions:

1. Hepatotoxic medications (additive risk)

• Isotretinoin, methotrexate, valproate, amiodarone, high-dose acetaminophen, antiretrovirals with hepatotoxicity signal. Avoid combination; if unavoidable, monitor LFTs more frequently.

2. Sedatives (additive GABAergic CNS depression)

• Benzodiazepines, barbiturates, gabapentinoids, alcohol, phenibut, GHB, baclofen. Effect is mild but real — particularly noticeable at higher gotu kola doses (>1000 mg/day).

3. Antidiabetic medications (theoretical hypoglycemia signal)

• Some animal data suggests mild hypoglycemic effect. Monitor blood glucose if combining with insulin or sulfonylureas.

4. Diuretics (theoretical additive)

• Mild diuretic effect reported in folk use; potential additive with prescription diuretics. Clinically minor.

5. Anticoagulants / antiplatelets (theoretical bleeding-time effect)

• Triterpenoid saponins have weak antiplatelet activity in vitro. Clinical bleeding events not reported but a flag.

6. CYP3A4 substrates with narrow therapeutic index

• Cyclosporine, tacrolimus, some calcium channel blockers, ergot derivatives. Theoretical interaction; clinical reports absent. Monitor if combined long-term.

7. Hormonal contraceptives

• No documented interaction.

8. Modafinil / armodafinil

• No documented interaction; theoretical mild GABAergic offset of modafinil's glutamatergic effect — not clinically significant.

CYP3A4 / CYP3A5 polymorphism: May modestly affect asiatic acid clearance. CYP3A5 expressers (CYP3A5*1, ~10% of Caucasians, ~30%+ of African / Asian populations) may have faster clearance and reduced exposure. Clinically minor.

UGT1A polymorphism: Glucuronidation is the major clearance route for centellosides. UGT1A1*28 (Gilbert syndrome variant, ~10% of Caucasians) is associated with slower glucuronidation of multiple substrates. Theoretical implication: Gilbert-syndrome carriers may have higher centelloside exposure and slightly elevated hepatotoxicity risk. Not clinically validated but plausible.

HLA alleles and idiosyncratic hepatotoxicity: No validated HLA marker for centelloside-induced hepatotoxicity. The hepatotoxicity cases that have been worked up immunologically appear idiosyncratic. If 23andMe reveals first-degree family history of severe drug-induced liver injury, take gotu kola hepatotoxicity signal more seriously.

COMT Val/Val vs Met/Met: No known interaction with gotu kola's central effects (GABAergic, not dopaminergic primarily).

For this athlete: Await June 2026 bloodwork ALT/AST baseline; await 23andMe UGT1A1 status before any continuous use >4 weeks. If Gilbert variant present, limit to 4-week trials with LFT monitoring at week 4.

For this athlete: Nature's Way standardized Centella asiatica 475 mg, ~$10 for a one-month supply at 500 mg once daily, is the right cost/quality tier for a 4-week trial. If continuing or escalating to twice-daily, upgrade to Pure Encapsulations or source TECA-grade through international pharmacy connections. Topical centelloside cream (any Korean K-beauty Centella product, ~$15) is a low-risk addition for mat-burn / bruise / abrasion management — strong topical evidence regardless of oral decision.

Quality flags:

• Always check "standardized to X% triterpenoids" or "X% asiaticoside" — non-standardized whole-herb products vary 10× in active content.
• Avoid products with proprietary blends that don't disclose dose.
• Heavy-metal contamination has been reported in Indian / Asian-sourced Ayurvedic herbs; prefer US/EU GMP-certified brands.

Baseline (before starting)

• ALT, AST (mandatory before any continuous use >4 weeks; pulled in this athlete's June 2026 bloodwork panel)
• GGT, alkaline phosphatase, total bilirubin (full LFT panel ideal)
• GAD-7 or HAM-A (if running anxiety-modulation trial)
• Subjective stress / anxiety VAS (daily 1–10 for 7 days pre-dose)
• Subjective cognitive performance VAS (daily 1–10 for 7 days pre-dose if running cognitive trial)
• Venous symptom assessment (if running venous-insufficiency indication) — ankle circumference, evening leg-heaviness VAS
• Wound / scar photographic baseline (if running wound-healing protocol — front torso, areas with active bruising/abrasions)
• 25(OH)D, ferritin, B12 (rule out anemia / deficiency-driven fatigue that gotu kola won't fix)

During use

• Daily: subjective anxiety, mood, stress VAS — compare weekly averages
• Weekly: subjective cognitive performance — single weekly check-in
• Weeks 4–6: symptom watch for hepatotoxicity — RUQ pain, fatigue out of proportion, dark urine, yellowing of sclera, nausea
• Week 4 if continuing: repeat ALT/AST — stop if any elevation >2× baseline
• For venous insufficiency users: weekly ankle circumference, evening leg-heaviness VAS
• For wound/scar users: weekly photo of affected area, same lighting/angle

Post-cycle (if discontinued or cycled)

• Subjective anxiety/stress baseline check at 1 and 2 weeks off — calibrates real benefit vs placebo/expectancy
• ALT/AST at 4 weeks off if any elevation seen during use — should normalize
• Venous symptoms — expect mild return of baseline symptoms within 2–4 weeks off